Background Fibromyalgia is a painful, debilitating illness with a prevalence of 0.5-5.0% that
affects women more than men. It has been shown that the diagnosis of fibromyalgia is …

Biologic therapies have revolutionized treatment of a number of diseases. Patents and
exclusivity for a number of biologics are expiring. This has created the opportunity for the …

Background Fibromyalgia (FM) is a condition characterized by widespread pain and is
estimated to affect 0.5-5% of the general population. Historically, it has been classified as a …

Fibromyalgia (FM), a complex chronic pain disorder affecting a heterogeneous patient
population, is an area of active basic and clinical research. Although diagnostic criteria for FM …

Psoriasis is a chronic, inflammatory, lifelong disease with a high prevalence (afflicting
approximately 1–5% of the population worldwide) and is associated with significant morbidity. The …

Background Clinicians are required to assimilate, critically evaluate, and extrapolate information
to support appropriate use of biosimilars across indications. Objectives The objective of …

Background Despite regulatory efforts to formalize guidance policies on biosimilars, there
remains a need to educate healthcare stakeholders on the acknowledged definition of …

Objective Regulatory approval of biosimilar versions of originator biotherapeutics requires
that new biological products be highly similar to originator products, with no clinically …

OBJECTIVE: To record practice patterns of treatment of acute gout in hospitalized patients.
METHODS: We performed a retrospective chart review of hospitalized patients diagnosed …

Yersinia, and Campylobacter. ReA is also commonly associated with spondylitis; sacroiliitis;
and enthesitis (inflammation of tendinous and ligamentous insertions). Unlike most forms of …